Late-breaking trial data at tvt demonstrate sustained safety and performance of watchman flx™ left atrial appendage closure device

Marlborough, mass., july 21, 2021 /prnewswire/ -- today, boston scientific (nyse: bsx) announced positive 24-month results from the pinnacle flx clinical trial assessing the safety and efficacy of the next-generation watchman flx™ left atrial appendage closure (laac) device for patients with non-valvular atrial fibrillation (nvaf).
BSX Ratings Summary
BSX Quant Ranking